Shelby Saunders

About Shelby

Shelby focuses on advising companies on regulatory compliance issues regarding international trade and export controls. She helps clients navigate trade sanctions issues and provides guidance related to the Committee on Foreign Investment in the US (CFIUS). She also assists on international transactions and complex matters concerning US export control laws and regulations.

View full bio

Admissions and credentials

New York

Experience

RPM Ventures Leads Firefly Aerospace’s Oversubscribed $175 Million Series D

November 12, 2024

Cooley advised early-stage venture capital firm RPM Ventures as the lead investor for Firefly Aerospace's oversubscribed $175 million Series D.

Related contacts

Kevin Rooney

Partner, San Francisco

Alison L. Tong

Associate, San Francisco

Grant Schweikert

Special Counsel, Washington, DC

Alfred Browne

Partner, Boston

Hailey Yook

Associate, San Francisco

Parker Erkmann

Special Counsel, Washington, DC

Shelby Saunders

Associate, New York

David Fletcher

Partner, Washington, DC

Christopher Kimball

Partner, Washington, DC

Kevin King

Partner, Washington, DC

Karen Tsai

Special Counsel, Washington, DC

Mark Windfeld-Hansen

Senior Counsel, Palo Alto

J.G. Harrington

Special Counsel, Washington, DC

Henry Wendel

Special Counsel, Washington, DC

Sarah Oliai

Associate, Washington, DC

Kris Tsao Cachia

Paralegal Specialist, San Francisco

Ron Metzger

Paralegal Specialist, San Francisco

Hayden Smith

Lead Quanitative Analyst, Boston

Related Practices & Industries

Venture Capital

Emerging Companies

Private Equity

CFIUS

Communications

Tax

Antitrust and Competition

Spacetech and Satellite

Avid Bioservices Announces $1.1 Billion Acquisition by GHO Capital Partners and Ampersand Capital Partners

November 6, 2024

Cooley advised Avid Bioservices (Nasdaq: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, on its definitive merger agreement to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.